E-LIB Suche - Ergebnisse für: Vulsteke, V

1

A20/TNFAIP3 heterozygosity predisposes to behavioral sympto..:

Daems, C. ; Sékulic, M. ; Vulsteke, V....
Brain, Behavior, & Immunity - Health. 2 (2020) - p. 100018 , 2020

Link: https://doi.org/10.1016/..

2

Microplate Differential Calorimetric Biosensor for Ascorbic..:

Vermeir, S. ; Nicolaï, B. M. ; Verboven, P....
Analytical Chemistry. 79 (2007) 16 - p. 6119-6127 , 2007

Link: https://doi.org/10.1021/..

3

Lectin binding sites during Drosophila embryogenesis:

Callaerts, P. ; Vulsteke, V. ; Loof, A..
Roux's Archives of Developmental Biology. 204 (1995) 4 - p. 229-243 , 1995

Link: https://doi.org/10.1007/..

4

A20/TNFAIP3 heterozygosity predisposes to behavioral sympto..:

Daems, C ; Sékulic, M ; Vulsteke, V...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474646/. , 2019

Link: http://www.ncbi.nlm.nih...

5

The C-terminus of NIPP1 (nuclear inhibitor of protein phosp..:

Beullens, M ; Vulsteke, V ; Van Eynde, A...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1221501. , 2000

Link: http://www.ncbi.nlm.nih...

6

Mapping of the RNA-binding and endoribonuclease domains of ..:

Jin, Q ; Beullens, M ; Jagiello, I...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1220430. , 1999

Link: http://www.ncbi.nlm.nih...

7

A20/TNFAIP3 heterozygosity predisposes to behavioral sympto..:

C. Daems ; M. Sékulic ; V. Vulsteke...
http://www.sciencedirect.com/science/article/pii/S2666354619300183. , 2020

Link: https://doi.org/10.1016/..

8

247P Real-world evidence of immune checkpoint inhibitor tre..:

Geldhof, V. ; Oeste, C.L. ; Verbiest, A.T.L....
ESMO Open. 9 (2024) - p. 102709 , 2024

Link: https://doi.org/10.1016/..

9

39MO Phase III ENGOT-En9/LEAP-001 study: Lenvatinib + pembr..:

Pignata, S. ; Marth, C. ; Moore, R.G....
ESMO Open. 9 (2024) - p. 103539 , 2024

Link: https://doi.org/10.1016/..

10

112P Close cardiovascular monitoring during the early stage..:

Delombaerde, D.L. ; Vulsteke, C. ; Van de Veire, N....
Immuno-Oncology and Technology. 20 (2023) - p. 100584 , 2023

Link: https://doi.org/10.1016/..

11

114P Real-world insights on pan-cancer immune checkpoint in..:

Verbiest, A.T.L. ; Delombaerde, D.L. ; Verhaert, M....
Immuno-Oncology and Technology. 20 (2023) - p. 100586 , 2023

Link: https://doi.org/10.1016/..

12

ENGOT-en9/LEAP-001: A phase III, randomized, active-control..:

Marth, C. ; Vulsteke, C. ; Rubio, M.J.R....
Gynecologic Oncology. 159 (2020) - p. 221 , 2020

Link: https://doi.org/10.1016/..

13

Phase 3, randomized, open-label study of pembrolizumab plus..:

Marth, C ; Tarnawski, R ; Tyulyandina, A...
https://discovery.ucl.ac.uk/id/eprint/10143542/1/93.full.pdf. , 2022

Link: https://discovery.ucl.ac..